about
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupDefining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.Innate immunity in host-microbial interactions: beyond B27 in the spondyloarthropathies.The juvenile-onset spondyloarthritides: rationale for clinical evaluation.The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.Primary prevention in rheumatology: the importance of hyperuricemia.ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patientsA Prospective Follow-Up of Adipocytokines in Cohort Patients With Gout: Association With Metabolic Syndrome But Not With Clinical Inflammatory Findings: Strobe-Compliant Article.Juvenile spondyloarthritis treatment recommendationsThe assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist.Coping strategies for health and daily-life stressors in patients with rheumatoid arthritis, ankylosing spondylitis, and gout: STROBE-compliant article.Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of ProlactinUndifferentiated spondyloarthritis: a global perspective.Ankylosing spondylitis and reactive arthritis in the developing world.Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.Inflammatory back pain.Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles.Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.Severe tophaceous gout and disability: changes in the past 15 years.Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.Epidemiology of rheumatic diseases. A community-based study in urban and rural populations in the state of Nuevo Leon, Mexico.Prevalence of back pain in the community. A COPCORD-based study in the Mexican population.Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.If three of my brothers have ankylosing spondylitis, why does the doctor say it is not necessarily hereditary? The meaning of risk in multiplex case families with ankylosing spondylitis.Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.Treatment Algorithms in Systemic Lupus Erythematosus.Association of regional and cultural factors with the prevalence of rheumatoid arthritis in the Mexican population: a multilevel analysis.Epidemiology of rheumatic diseases in indigenous populations in Latin-Americans.Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
P50
Q28138338-DFC43CB4-C9B5-4B1B-A5D2-B8CC9B031BCDQ30251968-2432D396-4F38-408A-ADD3-1252774C880AQ30417517-FDAE8F42-E01F-4D22-ACCF-05D7EB326A99Q33659233-B207AEA1-5932-427E-9FFF-BDB885108BD0Q34594335-A0E69CF4-64C0-4720-BC41-57B84AD2D901Q34739438-2CE6C688-37E0-45FC-A696-132ED2DC2CC6Q34983468-2A9A0691-22EB-43ED-BF7E-E7BF75E7648EQ34989826-5461AC66-4596-4F3A-AF55-F7009269C93DQ35645174-477BFE26-1B8E-4785-AFCC-5CA64C3B7274Q35761856-10ADFB7A-9CE5-4E38-8457-30383E2D24D7Q35842117-956B1421-CFDF-4603-AB05-C814B64F5990Q35857780-4ECD29A8-A6D0-41EA-9093-214629490D63Q36004879-95E23256-BCD8-4F4A-A748-41DF0977FDA8Q36112605-805CB7B6-9AA0-4DBE-B582-96EA41C3CC07Q36150980-64FAE5BA-34F6-4013-9E7D-421F83F93AABQ36566751-F124892A-93F5-472F-8B8F-516E750A489FQ36960221-824155BD-5149-49F0-B5C9-839D3D71B773Q37265662-D7F73D28-B2F6-4B7F-83E4-551B41436692Q37320554-D59B46C6-65A1-46F8-8C8C-E0F41E36B1FAQ37325983-69A7D547-10A1-4CDB-9B11-9B707102CC63Q37465518-099B6267-ECAF-47E0-B1E4-0723D51BD43CQ37553140-2679587E-DC27-4EE5-9EAA-BE899A0099AEQ37846264-6F73E59E-F30C-4266-8BAA-44587116F65CQ37871699-C1FE2A7D-1B65-43AB-96F9-B62947F1045AQ38053520-D35A41A1-00DC-40F7-9336-470030D763F4Q38362080-9C6916EA-A79B-4AD7-924D-BEA20EA2C2B5Q38759441-78646CFC-51F8-41B4-8A65-F2641F63B141Q39386597-40C3FDB4-4FFD-448B-A4EB-16C0CA77A540Q39844539-02BA41D2-0161-403F-9732-9491EE71775FQ39964864-A555827B-E010-4E9C-9CCE-E97535F677F1Q39964876-3C94AB22-12D1-4FA6-96C2-6737704503D4Q40263864-954D3A39-A67D-4573-933A-705CE050617BQ40405924-52483BCF-0E52-48F3-92DF-78C28B6DD0CFQ40492098-B06EBB03-2FF2-4C66-B22F-7065285897C1Q40626412-BA4EAE31-45CD-4E0A-BDAA-669A424EFC43Q40771281-60E635FE-ABC0-4D4B-AAC3-159F68FE51A4Q41207949-5DCF1880-354F-4C97-8111-4F7FEE199CC2Q41358508-74676F89-835E-4918-A0CC-487063989F52Q42410122-3FB1279D-9E1D-49A0-98CC-EEFA1B8787BBQ42651098-073271DA-D6D3-47C9-9009-CF6FB88D6C1A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Rubén Burgos-Vargas
@ast
Rubén Burgos-Vargas
@en
Rubén Burgos-Vargas
@es
Rubén Burgos-Vargas
@nl
type
label
Rubén Burgos-Vargas
@ast
Rubén Burgos-Vargas
@en
Rubén Burgos-Vargas
@es
Rubén Burgos-Vargas
@nl
altLabel
Ruben Burgos-Vargas
@en
prefLabel
Rubén Burgos-Vargas
@ast
Rubén Burgos-Vargas
@en
Rubén Burgos-Vargas
@es
Rubén Burgos-Vargas
@nl
P1006
P214
P1006
P21
P214
P31
P735
P7859
viaf-283531949